The FDA throws out the company’s second attempt at an accelerated approval.

While Roche, Lilly and Merck push on aggressively, Novartis throws in the towel.

Now in Bristol’s hands, BMS-986442 is set to deliver its first clinical data.

The group reaffirms pancreatic cancer promise with RMC-6236, but has it found the best dose?